Brussels, 22/12/2004 (Agence Europe) - The European Medicines Agency (EMEA) indicated in a press release that he had been informed by the US Pfizer laboratory that a clinical trial had demonstrated an increased risk of cardiovascular events among patients taking Celecoxib (brand name Celebrex). The agency has asked the laboratory to provide it with the results from this study and another trial funded by Pfizer. It is continuing to re-examine the whole of the medicines range belonging to the family of cyclo-oxygenase 2 inhibitors (COX-2). Re-examination was launched last October after the announcement by the German laboratory Merck of a withdrawal of another anti-inflammatory non-steroid, Vioxx. The price of Pfizer shares fell dramatically on Monday after the announcement of this problem, which also realaunched the debate of the quality of medicine assessments.